These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39127303)

  • 1. β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy.
    Kuo CS; Chen HS
    Diabetes Res Clin Pract; 2024 Sep; 215():111814. PubMed ID: 39127303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.
    Chen HS; Wu TE; Jap TS; Hsiao LC; Lee SH; Lin HD
    Diabetes Care; 2008 Oct; 31(10):1927-32. PubMed ID: 18556343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy.
    Cheng Q; Yang S; Zhao C; Wang Z; Feng Z; Li R; Ye P; Zhang S; Deng H; Zhou B; Long J; Gong L; Qing H; Luo C; Li Q
    J Diabetes; 2015 Mar; 7(2):182-91. PubMed ID: 24823280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity.
    Arnetz L; Hage C; Ekberg NR; Alvarsson M; Brismar K; Norhammar A; Mellbin L
    Growth Horm IGF Res; 2015 Dec; 25(6):298-303. PubMed ID: 26283275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.
    Shankar RR; Bao Y; Han P; Hu J; Ma J; Peng Y; Wu F; Xu L; Engel SS; Jia W
    J Diabetes Investig; 2017 May; 8(3):321-329. PubMed ID: 27740719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
    Lim S; An JH; Shin H; Khang AR; Lee Y; Ahn HY; Yoon JW; Kang SM; Choi SH; Cho YM; Park KS; Jang HC
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):215-23. PubMed ID: 21955147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes.
    Beljić-Živković T; Marjanović-Petković M; Vuksanović M; Soldatović I; Kanlić D; Topalov D
    Srp Arh Celok Lek; 2016; 144(9-10):497-502. PubMed ID: 29652465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D; Xu L; Teng R; Golm GT; Johnson J; Davies MJ; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
    Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
    Sharma M; Beckley N; Nazareth I; Petersen I
    BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
    Sun Y; Yan D; Hao Z; Cui L; Li G
    Med Sci Monit; 2020 Apr; 26():e921891. PubMed ID: 32240122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
    Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.